2022 President-Elect Nominee: Daniel J. Briceland, MD
It is an incredible honor and privilege to be nominated to serve as Academy president. I am grateful for the opportunity to serve at this critical time for our members and profession as we continue to recover from the many challenges faced during the pandemic. In addition, our Academy will be in the midst of transitioning to a new CEO following the retirement of David Parke II, MD, whose tenure resulted in many innovative and transformational changes, such as the IRIS® Registry.
Read more at AAO.org.
2022 Digest (Vol 32 No 1)
Allegations of failure to diagnose are common in medical malpractice lawsuits against ophthalmologists, and diagnostic error is an issue of ongoing concern in the healthcare community. In fact, one of the “Top 10 Patient Safety Concerns” listed in an ECRI (formerly the Emergency Care Research Institute) and Institute for Safe Medication Practices (ISMP) 2022 special report is “Cognitive Biases and Diagnostic Error.” We examine solutions.
(some links within this PDF document may not work in all browsers due to security controls or other reasons. To correct this issue, the document may be downloaded and then the links should work, or copied from the document directly into a new window in your browser)
Take Time Out
August 9, 2021
Dear OMIC Insureds:
OMIC has received reports of “wrong” events associated with intravitreal injections. These include wrong condition, wrong dose, wrong drug, wrong eye, and wrong patient. To ensure that the correct drug and dose are injected into the correct eye every time, the ophthalmologist needs to lead a time out before each injection. A time out provides the opportunity to confirm that the patient, medical record, and ophthalmologist are in agreement.
In a 2-minute video, Dr. Pauline Merrill shares her tips for reducing the risk of error when administering intravitreal injections. You won’t want to miss this!
Click below to watch the video.
If you have questions, please contact OMIC Risk Management by calling 1-800-562-6642, enter 4 for the Risk Management group or email us at riskmanagement@omic.com.
Regards,
Michelle Pineda, MBA, OMIC Risk Manager
February 2021 Bulletin: COVID-19 Vaccinations
Some policyholders have expressed interest in administering COVID-19 vaccines. Vaccination services are complex, especially for physicians who do not customarily vaccinate patients. The COVID-19 vaccine landscape is also dynamic: different vaccines, different dosing schedules, and varying availability of vaccines add to the challenge of providing this service.
In response, OMIC has created a resource outlining medical professional liability risks associated with offering the COVID-19 vaccine and recommendations to mitigate those risks https://www.omic.com/covid-19-vaccine-risk-management-considerations-and-consent/. The resource also includes a sample patient screening and vaccination consent form.
If you have questions about these risk management resources, contact us for confidential risk management advice by emailing us at riskmanagement@omic.com.
OMIC is extending coverage to its insureds for the administration of COVID19 vaccinations. Questions about coverage should be directed to OMIC’s Underwriting Department at (800) 562-6642, ext. 1, or omic@omic.com.
Thank you,
Linda D. Harrison, PhD
Vice President, OMIC Risk Management
OMIC named Outstanding Captive of the Year for 2020
OMIC has been chosen Outstanding Captive of the Year for 2020 by the Captive Insurance Companies Association (CICA). A “captive insurer” is generally defined as an insurance company that is wholly owned and controlled by its insureds; its primary purpose is to insure the risks of its owners, and its insureds benefit from the captive insurer’s underwriting profits.
To date, OMIC has returned more than $90 million in policyholder dividends and helped stabilize the market for ophthalmology professional liability insurance.
This prestigious award was created to recognize companies that are creative and successful in the way they manage net results, provide exceptional service to its owners, prevail over difficult times or situations, and gain acceptance, recognition, and a positive reputation among agencies, regulators, and colleagues in its industry. CICA also noted the tremendous impact OMIC has had on risk management and patient safety around the world.
Tim Padovese, OMIC President and CEO
To be recognized in such a way among the 3,200 captives operating in the U.S. is truly an honor for our board, employees, and members.
Tim Padovese, president and CEO of Ophthalmic Mutual Insurance Company (OMIC), notes that his company has avoided trying to become “all things to all people,” instead remaining “laser focused” on covering the professional liability of ophthalmologists and their practices.
That focus has allowed OMIC to deliver to its members a combination of expertise and excellent customer service that, among other things, has produced a 97 percent customer retention rate—and the Captive Insurance Companies Association (CICA) 2020 Outstanding Captive Award.
To see the full CICA article and interview here.
